Trial Profile

Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms TOP 1501

Most Recent Events

01 Feb 2022 Results assessing perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer, published in the Journal of Thoracic and Cardiovascular Surgery
01 Nov 2019 Planned End Date changed from 1 Jan 2027 to 1 Mar 2026.
12 Feb 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com